Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reirradiation for Locally Recurrent Non-Small Cell Lung Cancer
NCT07835789Phase 2Not yet recruiting
- Sponsor
- NRG Oncology
- Start
- Dec 2026
- Primary completion
- Sep 2029
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by NRG Oncology. Primary endpoint: Progression-Free Survival at 5 years. Planned start Dec 2026; status: not yet recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07835789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07835789.